Desmethyl tocopherols for protecting cardiovascular tissue

Abstract

The present invention involves the use of desmethyl tocopherols such as gamma tocopherol for the protection of cardiovascular tissue from nitrative stress. While mechanisms other than scavenging of reactive nitrogen species may be involved, desmethyl tocopherols exhibit significant protection and may be utilized to treat or help prevent cardiovascular particularly arterial vascular disease. The desmethyl tocopherols may be administered dietarily or parenterally when a more direct dosage is desired. Both routes may be utilized together or separately to optimize therapeutic and prophylactic benefits. The lessening of damage induced by reactive nitrogen species leads to the lessening of arterial blockage in thrombosis.

Description

[0001] Priority is claimed from provisional application U.S. Ser. No. 60 / 186,455 filed on Mar. 2, 2000, and incorporated by reference herein.[0002] The present invention relates to concentrated preparations of desmethyl tocopherols, including but not restricted to gamma tocopherol (.gamma.T), which localize to lipid environments in cardiovascular tissue and scavenge reactive nitrogen species (RNS) by virtue of a phenolic structural element lacking one or more methyl substituents on the phenolic ring system. The capability to scavenge RNS imparts cardiovascular protective properties to the compound.[0003] Tocopherols are a class of lipophilic, phenolic compounds of plant origin. The major tocopherol found in mammalian tissue is alpha tocopherol (.alpha.-tocopherol or .alpha.T or vitamin E) FIG. 1, although significant quantities of demethylated (desmethyl) forms (particularly .gamma.-tocopherol or .gamma.T) FIG. 1, are also present. .alpha.-Tocopherol acts as a free radical scavenger...

AI Technical Summary

Benefits of technology

[0037] In practice, the .gamma.-tocopherol (or other desmethyl tocopherols) would be formulated in a manner allowing safe delivery of effective doses to humans. The .gamma.-tocopherol (or other desmethyl tocopherols) can be absorbed orally by mammals and could be used by oral administration. The .gamma.-tocopherol (or other desmethyl tocopherols) could be administered topically to inflamed skin or gum / mouth or other mucosal tissue as a cream or gel, or could be inhaled as an aerosol. The relative stability and lipophilicity of .gamma.-tocopherol (and other desmethyl tocopherols) make these compounds amenable to delivery in numerous possible formulations. Derivatives of .gamma.-tocopherol (or other desmethyl tocopherols) which retain the structure of a phenolic ring lacking a H atom near the --OH group would also be useful as a protectant against nitrative stress in neurodegenerative conditions; intraperitioneal or intravascular administration in appropriate media may also be used when desired.

Problems solved by technology

End-stage disease is characterized by ischemic damage to the heart and major perfused organs, and with increased risk of occlusive thrombus as portions of plaque disintegrate and initiate coagulation cascades.

Initial studies using relatively small populations (<100 subjects) failed to find a correlation between .alpha.-T and vascular disease, although these studies have been criticized for failure to normalize .alpha.T to lipid content, which might confound the interpretation of the data (28).

Data from large-scale, prospective, controlled tocopherol supplementation trials is currently being analyzed and published with somewhat paradoxical results.

The quantitative discrepancies between epidemiological data and intervention studies are disturbing.

While extensive data has been collected on .alpha.-tocopherol as a possibly beneficial molecule in cardiovascular disease, very little data has been collected on .gamma.T.

Images